Clinical Trial Update: Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study [Phase 2]

View source ↗

Summary

Phase II trial evaluating Kanglaite to reduce radiotherapy toxicity in head and neck cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Kanglaite

Snippet

Sponsor: First Affiliated Hospital of Harbin Medical University | Conditions: Head and Neck Cancer, Radiotherapy | Phase 2 | Status: COMPLETED | Results posted: 2021-06-23